2 July 2016

Seeing in 3D

Ben Jaglom

Eye tracking specialist Seeing Machines (SEE) has won a deal to supply its technology to Toshiba’s new glasses-free laptop.

The AIM-quoted Australian minnow will be supplying its faeAPI technology- which tracks the movement of the eyeball – for Toshiba’s Qosmio F750, which the company enthuses is the world’s first 3D laptop to not require special glasses. The company will receive a royalty for each unit sold by Toshiba. It is built into the laptop’s webcam which then tracks the movement of the eyeball to produce a 3D image.

Seeing's CEO Ken Kroeger declared that it is 'only the beginning of a new era in glasses-free 3D'. He enthused that SuperD (its partner in the technology) chose Seeing as it develops technology that is 'uniquely able to provide face tracking with the required accuracy and reliability' adding that he believes this launch is 'the first of many.'

Prior to the announcement analysts at paid-for research house Edison were forecasting pre-tax profits of AUD $1.3 million (£850,000) on sales of AUD$ 8.7 million for the year to June 2011. In 2012 it is pencilling in profits of AUD $1.9 million on turnover of AUD $10. 8million. EPS of 0.3 cents (0.2p) and 0.4 cents (0.26p) are forecast for 2011 and 2012, respectively.

Recommended by Growth Company Investor last October at 3.5p the shares currently trade at 2.5p. The highly volatile shares have traded between a range of 1p to 4p over the last four years, with the company having done little to generate a significant rerating of its prospects. While the deal should provide some increased momentum we retain our hold rating for now.

Tags: 3D Technology, Australian businesses, Laptops, Technology in Australia

Cash Shells 2015

Published in September 2015 this annual research report provides a comprehensive overview of cash shells on the Main Market, AIM and PLUS landscape. Order your copy today

 

Superb investment toolkit for private investors

SharePad is the new web-based service from ShareScope. Easier to use and more powerful. Perfect for tablets, Macs and Windows PC. Covers ALL your investment requirements.

Growth Company Investor: free trial

Since 2008, our share tips outperformed the benchmark by 281%. Take a free trial and get access to our recommendations today. Start free trial now.

Directors' Pay on AIM 2015

The most comprehensive review of AIM directors' pay available, and this year includes a record sample of 1000+ AIM-quoted companies. The full report is available to order for £385 + VAT. Click here for more info

 

Latest small-cap and growth company news

Daily coverage of small-cap company stocks on London's junior markets AIM and PLUS, breaking news, stock research and latest share price information for investors. Full sector coverage with all the latest news on smaller listed companies, updated several times a day with financial reports, trading statements and links to further web resources.

Popular News

Latest News

The robots are coming

Recent AIM newcomer Blue Prism (AIM: PRSM) has released a promising set of maiden results for the half year to April. Revenues grew by a handy 21 per cent and momentum seems to be accelerating with 33 new customers added to the 57 in place at the end of October. 

Avingtrans returns cash and remains a Buy

Having turned most of its market cap into cash through the sale of its aerospace division, it’s no surprise that Avingtrans (AIM: AVG) has been a very defensive stock during the recent turmoil. We now have some more details on the return of cash to shareholders which was promised as part of the disposal.

Omega investing in growth

Omega Diagnostics results looked positive and highlighted the progress being made in getting important new products to market. The investment to support those efforts will depress profits this year; but the market seems willing to look through this with Omega being a rare stock to be trading above its pre-Brexit level.

Stadium hit by profit warning

Stadium Group shares have been hit by a profit warning. This is a particular blow given the company’s progress in repositioning itself into a higher quality, design-led business.

Verona raises £42m to fund drug trials 

Verona Pharma (AIM: VRP) has raised an impressive £42 million net of costs which will fund phase II trials for its RPL554 compound. This drug targets severe respiratory diseases, in particular the 65 million worldwide sufferers from COPD (chronic obstructive pulmonary disease).

Income attractions at Belvoir

It’s fair to say that buy-to-let landlords have been under George Osborne’s cosh. He’s introduced a raised stamp duty rate and withdrawn higher-rate tax relief. However, Belvoir Lettings has seen little change in the market as far as its core lettings agency business is concerned. Furthermore, the shares have responded positively to a major acquisition which makes Belvoir the largest UK lettings agent.

More News